Background: The Cardio-Kidney-Metabolic (CKM) syndrome represents a clinical continuum where metabolic disorders, chronic kidney disease (CKD), and heart failure (HF) mutually exacerbate cardiovascular risk. Despite international guidelines recommending SGLT2 inhibitors (SGLT2i) as a cornerstone of treatment across the entire ejection fraction spectrum, a significant therapeutic gap persists in clinical…